Zehner J, Klaus D, Klumpp F, Lemke R
Klin Wochenschr. 1976 Nov 15;54(22):1085-93. doi: 10.1007/BF01469112.
The influence of amitryptiline, theophylline and furosemide on the concentration of cyclic-AMP and plasma renin activity (PRA) was investigated in renal vein plasma. Additionally, the stimulating effect of furosemide on the PRA after application of the beta-adrenergic receptor antagonists propranolol and practolol and the cyclic AMP concentration in the plasma were measured. All drugs were given intravenously. After amitryptiline cyclic-AMP concentration increased about 1.5-fold compared with the basal value,PRA was not altered. After theophylline cyclic-AMP concentration increased about 1.2-fold, PRA 2.0-fold compared with the basal value, PRA was not altered. After theophylline cyclic-AMP concentration increased about 1.2-fold, PRA 2.0-fold coa increased within 7 min and no further increase was observed till the 15th min. After practolol cyclic-AMP concentration and PRA decreased about 20% compared with the basal value within 10 min. The stimulating effect of subsequently applied furosemide on PRA was not altered, but the cyclic-AMP concentration was not changed in this time by furosemide. After propranolol cyclic-AMP concentration and PRA decreased about 20% compared with the basal value. The cyclic-AMP concentration was not influenced by the following furosemide application, in agreement with the findings after practolol, however, PRA could be stimulated only in 36% of these patients under beta-receptor blockade. Our results show that changes of the concentrations of cyclic-AMP and of PRA are independent of each other. An elevated intracellular cyclic-AMP level due to the inhibition of phosphodiesterase is as a single factor unable to stimulate renin release. Our results give no evidence of a direct involvement of the adenylcyclase-system in the mechanism of renin release. The effect of propranolol and practolol on the basal value of PRA and cyclic-AMP is equal. The different influence of 10 mg propranolol and 20 mg practolol on the stimulating effect of 40 mg furosemide on the PRA can be interpreted as a dosage problem.
研究了阿米替林、茶碱和呋塞米对肾静脉血浆中环磷酸腺苷(cyclic-AMP)浓度和血浆肾素活性(PRA)的影响。此外,还测定了在应用β-肾上腺素能受体拮抗剂普萘洛尔和普拉洛尔后呋塞米对PRA的刺激作用以及血浆中环磷酸腺苷的浓度。所有药物均通过静脉注射给药。给予阿米替林后,环磷酸腺苷浓度较基础值升高约1.5倍,PRA未改变。给予茶碱后,环磷酸腺苷浓度升高约1.2倍,PRA升高2.0倍,PRA在7分钟内升高,直至第15分钟未观察到进一步升高。给予普拉洛尔后,环磷酸腺苷浓度和PRA在10分钟内较基础值降低约20%。随后应用的呋塞米对PRA的刺激作用未改变,但此时呋塞米未改变环磷酸腺苷浓度。给予普萘洛尔后,环磷酸腺苷浓度和PRA较基础值降低约20%。环磷酸腺苷浓度不受随后应用的呋塞米影响,这与给予普拉洛尔后的结果一致,然而,在β受体阻滞剂作用下,只有36%的患者PRA可被刺激。我们的结果表明,环磷酸腺苷浓度和PRA的变化相互独立。由于磷酸二酯酶抑制导致的细胞内环磷酸腺苷水平升高作为单一因素无法刺激肾素释放。我们的结果没有证据表明腺苷酸环化酶系统直接参与肾素释放机制。普萘洛尔和普拉洛尔对PRA和环磷酸腺苷基础值的作用相同。10mg普萘洛尔和20mg普拉洛尔对40mg呋塞米刺激PRA作用的不同影响可解释为剂量问题。